This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program), supports research to evaluate the role of the extracellular matrix (ECM) in triple negative breast cancer (TNBC) tumorigenesis, metastasis, and drug response. The $214,583 award to Tulane University will be used to 1) investigate how TNBC ECM composition changes pre- and post-chemotherapy treatment, and 2) assess the utility of 3D in vitro TNBC ECM models for screening cellular responses to therapy. This work aims to identify key ECM proteins that regulate TNBC progression and drug resistance, particularly in African American patient populations, and provide insights on molecular markers for prognosis and novel ECM-based drug targets. The project period runs from April 1, 2025 to March 31, 2027.
Generated 3/25/25, 3:28 AM